Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA03 - Biomarkers for Immunotherapy: Are All Relevant?

    • 10:45 - 11:45
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      MA03.02 - TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

      10:50 - 10:55  |  Presenter: Edward B Garon

      • Abstract

      Loading...

  • +

    P14 - Immunotherapy (Phase II/III Trials) - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P14.07 - PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC

      00:00 - 00:00  |  Presenter: Alexander Spira

      • Abstract

      Loading...

  • +

    P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P47.05 - A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

      00:00 - 00:00  |  Presenter: Melissa L Johnson

      • Abstract

      Loading...

  • +

    P53 - Novel Therapeutics and Targeted Therapies - Others

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P53.06 - A Multi-Phase Quality Initiative to Improve Processes of Care for Non-small Cell Lung Cancer (NSCLC) in US Community Cancer Centers

      00:00 - 00:00  |  Presenter: Matthew Smeltzer

      • Abstract

      Loading...

  • +

    P60 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P60.11 - Trends in Molecular Testing for Metastatic Non-Small Cell Lung Cancer in The US Oncology Network Community Practices

      00:00 - 00:00  |  Presenter: Nicholas J Robert

      • Abstract

      Loading...

    • +

      P60.13 - MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study

      00:00 - 00:00  |  Presenter: Makenzi Colleen Evangelist

      • Abstract

      Loading...

  • +

    IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape with Novel Strategies

    • 13:15 - 14:15
    • 9/09/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS05.01 - Welcome and Introductions

      13:15 - 13:20  |  Presenter: David R. Gandara

      • Abstract

      No abstract available for this presentation

    • +

      IS05.02 - The Evolving Biomarker Landscape in Advanced NSCLC

      13:20 - 13:35  |  Presenter: David R. Gandara

      • Abstract

      No abstract available for this presentation

    • +

      IS05.03 - KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC

      13:35 - 13:50  |  Presenter: Alexander Spira

      • Abstract

      No abstract available for this presentation

    • +

      IS05.04 - Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC

      13:50 - 14:05  |  Presenter: Afshin Dowlati

      • Abstract

      No abstract available for this presentation

    • +

      IS05.05 - Discussion

      14:05 - 14:15

      • Abstract

      No abstract available for this presentation

  • +

    OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation

    • 18:45 - 19:45
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      OA15.01 - Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

      18:45 - 18:55  |  Presenter: Alexander Spira

      • Abstract

      Loading...

    • +

      OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

      19:05 - 19:15  |  Presenter: Alexander Spira

      • Abstract

      Loading...

  • +

    MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC

    • 18:45 - 19:45
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      MA14.03 - Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib

      18:55 - 19:00  |  Presenter: Ferdinandos Skoulidis

      • Abstract

      Loading...